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Malaria has been part of Peruvian life since at least the 1500s. While Peru gave the world quinine, one of the first
treatments for malaria, its history is pockmarked with endemic malaria and occasional epidemics. In this review,
major increases in Peruvian malaria incidence over the past hundred years are described, as well as the human
factors that have facilitated these events, and concerted private and governmental efforts to control malaria.
Political support for malaria control has varied and unexpected events like vector and parasite resistance have
adversely impacted morbidity and mortality. Though the ready availability of novel insecticides like DDT and
efficacious medications reduced malaria to very low levels for a decade after the post eradication era, malaria
reemerged as an important modern day challenge to Peruvian public health. Its reemergence sparked collaboration
between domestic and international partners towards the elimination of malaria in Peru.
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Francisco Pizarro y González’s avaricious invasions of
Peru during the 1500s likely spread malaria to the Incas.
As a result, malaria would have predominated on the
coastal plains, Andean foothills, and the interandean val-
leys. In the 1600s, Peru gave the world Cinchona tree
bark, the source of quinine, which was the first effective
anti-malarial used worldwide [1].
As the 20th century began, the Andes divided Peruvians
between the Pacific coast and the Amazon. Both regions
suffered childhood malaria exposure, leading to partial im-
munity (Plasmodium vivax, Plasmodium falciparum, and
Plasmodium malariae). Andeans were immunologically
naïve because vectors were absent above 1,500 m. The in-
telligentsia falsely assumed that Andeans had a racial
weakness for malaria because outbreaks increased when
they migrated to the coast. Such migration increased when
plantations and associated businesses required workers
during sowing and harvesting between March and August,
which coincided with peak Anopheles densities due to in-
creased breeding aided by seasonal rain and stagnant
water accumulation. Andean workers had little access to
preventative measures or treatment [2,3].* Correspondence: Sean.Griffing@gmail.com
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reproduction in any medium, provided the orPeruvian malaria prevalence has been influenced by
pulses of immunologically naïve hosts confronting malaria
for economic reasons, waxing and waning support for
malaria control, and the loss of vector and parasite control
measures (Figure 1).
Early malaria control policy
As the 20th century began, mosquito populations were
controlled by mosquito nets, home fumigation, metal
roofs, and draining or spraying water reservoirs with Paris
Green or oil. The first national malaria control law came
in 1916 after a coastal epidemic. Landowners were re-
quired to distribute quinine, destroy Anopheles larvae, and
separate living quarters a minimum distance from rice
paddies and sugar-cane fields. Quinine and metal roofing
were no longer taxed. Some complied, maintained a med-
ical service, provided quinine, and cleaned canals and
ditches. They were unlikely to drain wetlands considered ir-
rigation reservoirs or reconstruct housing. In the Amazon,
a philanthropic landowner society managed a hospital from
1908 to 1918, with state support thereafter [2].
Compliance was inconsistent. In the 1930s, doctors and
planters argued whether rice cultivation was associated
with the patchy coastal malaria distribution. Doctors fa-
vored more separation of irrigated fields and worker living
quarters, planters less. It was sometimes difficult to pro-
vide medical care because of sparse medical staff. Ade-
quate treatment was limited by the belief that waterLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.






















































































P. malariae and P. ovale
Figure 1 This figure reports annual estimated malaria cases in total and by species, when available. It also reports a number of significant
events in Peruvian malaria control. Estimate quality likely varies based on multiple unmeasured factors. For example, the 1939 estimate may have
occurred prior to suitable infrastructure. In addition, numbers reported for 1991–1994 and 1996–1999 were based on visual estimates from line
and bar graphs and are reported for qualitative analysis [2,4-7].
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dosed or overdosed with quinine and prescriptions
sometimes disguised using unfamiliar names due to side
effects [2].
A major Amazonian epidemic (likely P. falciparum)
occurred during 1932 in Cuzco department, which was
larger than local epidemics going back to at least 1898.
Workers on the provincial outskirts were infected in
August within the territory of the Machiguenga tribes.
Recent deforestation, road building, and heavy rains led
to puddles and stagnant water pools where mosquitoes
bred. The epidemic spread rapidly along rivers and
reached the Andean foothills, aided by the movement of
merchants, workers, and fleeing citizens. The public
health response was slow because Health Board was
leaderless and the central government was disconnected
from the Amazon. Staff unable to speak Quechua
deployed amidst corruption accusations and adulterated
quinine. The epidemic ran its course by May 1934. Out
of a population of 25,000, there were 6,000-10,000
deaths and 15,000 sick. This led to the development of
the Cuzco Health Directorate Anti-malarial Service [2].
Peru centralized its public health response in 1933 by
creating the Health Directorate Hygiene and Prophylaxis
Service, which purchased wholesale quinine from the
National Agrarian Society. Initial efforts focused on mal-
aria control in coastal Carabayllo. In 1937, another study
was started in Cañete, south of Lima. These groups
united to form the Malaria Expert Department of therecently created Public Health, Work, and Social Fore-
casting Ministry, which conducted malaria campaigns
and constructed malaria hospitals. In 1939 the Health
Ministry said malaria control was “meager, almost null”
and that in certain regions it was “something that no
one complained about or commiserated with; they ac-
cepted it as part of life.” Amazonian malaria control was
thought impossible or not a priority. An observer said,
“malaria will not disappear, while the waters are not
channeled…while the swamps are not drained; all things
that the doctors don’t know how to do” [2].
In 1941, the ministry created the National Rural Sanita-
tion Antimalarial Service, which provided assistance, pre-
vention, and statistics. Eight anti-malarial services were
created in Lima, Cuzco, Ayacucho, Cañete, Chancay,
Camaná, and the Moche and Tambo valleys. Road con-
struction and public projects were supervised to disrupt
larval breeding pools, hospitals were improved, and the
supply of quinine was increased [2]. During the 1941 war
with Ecuador, both armies suffered from malaria [8]. Due
to yellow fever deaths in March and April, the Peruvian
Director of Health asked the Rockefeller Foundation (RF)
to take over yellow fever and malaria services under a co-
operative agreement. The foundation expanded funding to
the country and assigned a staff member [9].
In 1942, the Ministry became the Public Health and Social
Assistance Ministry which increased the national services
autonomy, staff, and budgets [2]. The Pan-American confer-
ence of 1942 led to the development of the Interamerican
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750 Peruvians and functioned until the 1970s with
United States financial and technical support. In the
early years, SCISP spent $1,350,000 dollars on hygiene
education and an Amazon hospital, as well as public
health projects in coastal Chimbote. Chimbote had been
chosen for the first national steel works and fishery
and it was thought this would encourage an influx of
immunologically naïve people and another malaria epi-
demic. SCISP’s projects included draining seven swamps
that covered 887,000 square meters, the installation of
potable water systems, and the construction of a modern
hospital [2]. The Pan American Bureau also contributed
two staff members to Peru and had a close relationship
with the country’s malaria services by 1944. The bureau
contributed lab and field tests that led to the substitu-
tion of copper arsenite for Paris Green after WWII
made it too expensive. They also provided assistance in
the design and construction of the Peruvian copper ar-
senite factory [2,8,10]. Meanwhile, some argued that the
Amazon would be habitable and profitable if public
health was prioritized [2].
Between 1941 and 1948, the RF gave funds to Peru for
various malaria efforts with support gradually decreased
as government payments increased [2]. The RF’s initial
malaria program goal was the eradication of Anopheles
pseudopunctipennis from the Pacific Coast valleys with
Paris Green starting with Lurín in 1943 [11]. The pres-
ence of virulent Bartonella bacilliformis in the upper
valley kept non-immune staff from visiting; it was dan-
gerous to stay overnight and impossible to make the
round trip within daylight hours because it was in-
accessible by car [12]. Other difficulties included drain-
age, seasonal changes in rainfall and water levels, and
scarce labor [11]. Controlling the vector was inexpen-
sive, but contemporary reports concluded eradicating it
would require effort across the valley. Funds were
increased four-fold and staff from the National Malaria
Service received training, which shifted their focus from
treatment to control [13]. The RF concluded that con-
trol was possible, but that eradication was not [2,14].
The RF also provided a survey and consultancy to
the government regarding re-organizing the National
Health Department, establishing local agencies, and ad-
vocating for full time staff. The department of Ica,
which contained three of the fifty coastal valleys, was
chosen for a model health service including malaria
control. Later, another program was started in Arequipa
[13,15]. The RF also contributed to the creation of the
National Institute of Hygiene [15].
The impact of DDT vector control
The RF introduced DDT to Peru in 1946. By 1947, the
National Malaria Service was spraying DDT in 16 coastalvalleys. By 1953, DDT was being sprayed in 47 coastal val-
leys and three in the Amazon. Malaria morbidity went
from 945 per 100,000 (1941–1946) to 490 per 100,000
(1947–1958). In 1944, there were 95,349 malaria cases,
but 20,000 by 1950. The coast accounted for 67% of cases
that year (803 per 1,000) and in the Amazon 33% (295 per
1,000) [2]. After the 1950s control efforts, there were less
than 1000 cases a year bordering Ecuador, Colombia, and
Brazil, more than 80% of which were P. vivax and none P.
falciparum [16].
By 1957, malaria control shifted to eradication through
SCISP and UNICEF support. The country organized a
Malaria Eradication National Service with funding from
the National Health Fund and Social Welfare. UNICEF
provided vehicles, equipment, insecticides and medica-
tions. SCISP contributed technical assistance, adminis-
tration, and medication. It was projected that five years
of aggressive anti-malarial and insecticides application
would eradicate malaria and incidentally control yellow
fever, dengue, and murine typhus [2].
The effort began in November 1957 with 67,633 DDT
coastal sprayings. Malaria disappeared from some de-
partments that same year. Between 1959 and 1962,
sprayings were higher than 600,000 per year in five
zones. By 1965, coastal Piura, Tumbes, La Libertad, Ica,
Callao, Arequipa and Huancavelica had three years of
interrupted transmission and there were only 1,500
cases countrywide [17]. By 1970, almost the entire
coast was malaria free, as well as the interandean val-
leys, and the southern Peruvian Amazon [2,18]. Unfor-
tunately, malaria increased again in 1970 as mosquitoes
became DDT resistant and malaria control program
funding decreased [2].
The success of malaria eradication, and an increa-
singly urbanized coast, encouraged Andean migration
to the coast and Amazon. Chimbote went from 4,000
inhabitants in 1946 to 50,000 inhabitants by 1958. Still,
between 1946 and 1955, malaria was the first ranked
cause of Peruvian morbidity and the 10th ranked for
mortality. Malaria control efforts between 1940 and
1972 caused a social shift from a rural mountain popu-
lation to a coastal urban one [2].
DDT use had halted in Loreto, an Amazonian depart-
ment that constitutes one fourth of Peru’s area, in 1988,
though bed nets were still used [17,19,20]. Between 1992
and 1997 malaria increased four-fold in Peru and fifty-
fold in Loreto [17,19].
Malaria reemergence after malaria eradication
Peruvian P. vivax cases gradually increased from 1,484
cases in 1963 to 39,122 cases in 1987 [4]. During the
1980s, Peruvian malaria control was unstructured [2]. A
P. malariae outbreak occurred in Pampa Hermosa in
the western Amazon, during 1986–1987, where before
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malaria cases were caused by Amazonian P. falciparum
[22]. Three years later, there was a P. falciparum outbreak
on the northern coast, no cases in 1988, and 65 in 1989
[4,20]. In 1990, there were 28,882 malaria cases, of which
131 were P. falciparum, principally in the northern coastal
departments of Piura and Tumbes [4].
Malaria began to increase on the coast and along the
periphery of Loreto. In 1991, Loreto had 140 P. falciparum
cases with a Pastaza River valley outbreak, while a
major outbreak began on the northern coast [17,20].
Cases were reported in the northern Loreto in Gueppi,
to the west on the Pastaza River and in Yurimaguas, to
east in Baja Putumayo and Atlántida, and to the
southeast in Requena-Buenas Lomas [21]. In 1992,
Pampa Hermosa reported its first P. falciparum cases.
A year later, there were 436 P. falciparum cases, 205 P.
vivax cases, and a few P. malariae cases [21]. Malaria
was also reported in northwest Andean Cajamarca and
P. falciparum incidence was increasing in the coastal
departments [5,20].
Plasmodium falciparum was first reported in Padrecocha,
a riverine village of 1,400 inhabitants near the major
city of Iquitos, in 1994 [5,17]. Iquitos is the largest city
in Loreto with a population of 305,514 in 1993 and
345,000 in 1999, while the remainder of Loreto had
474,000 inhabitants along the Amazon tributaries. It
grew due to oil exploration, mining, and drug traffick-
ing [17,19,23]. Andeans were encouraged to move to
Iquitos due to government policy and fighting between
the military and Shining Path during the 1980s and
1990s. This led to rural expansion and deforestation
with an estimated 4,257 forest hectares cleared between
1983 and 1995. Another settlement extended away
from Iquitos by following an unfinished road between
Iquitos and Nauta, along with deforestation. Habitat
changes including rice cultivation, irrigation canals,
and aquaculture led to flooding that increased vector
populations [19].
After the heavy rains and flooding caused by El Niño,
conditions were ideal for the blooming of major epi-
demics [24]. By 1997, there were 121,268 slide con-
firmed malaria cases, of which 45% were P. falciparum,
though P. malariae remained rare. Loreto accounted for
67.2% of malaria cases in Peru. While there were out-
breaks throughout Loreto, most cases occurred around
Iquitos in two high transmission areas, along the Nanay
River downstream of Iquitos and along the Iquitos-
Nauta road. Elsewhere in Loreto, the communities
around the Yavarí and Pastaza Rivers had high trans-
mission. Malaria was hypoendemic, with periods of
mesoendemicity [17]. As the 1990s ended, the Amazon
basin and the northern Pacific coast accounted for 85%
of malaria cases and 95% of P. falciparum cases [5].The Health Ministry organized a network of 329
health facilities and 850 promoters for observing Ama-
zonian malaria to 1) diagnosis and treat malaria; 2) re-
duce disease severity and transmission; and 3) lower
cost. Only 137 facilities could diagnose malaria by
light microscopy, while the remainder collected blood
smears. All facilities were authorized to provide treat-
ment after smears were malaria verified. In 2001, there
were 35,632 malaria cases in Loreto, of which 9,654
were P. falciparum with the main vector Anopheles
darlingi [25]. Peruvian self-treatment was uncommon,
despite pharmacies providing anti-malarials without
prescription, because government treatment was free [5].
During 2004, malaria control was transferred to the
National Health Strategy for the Prevention and Control
of Tropical Diseases from the National Control Pro-
gram, principally financed by national funds, but also
USAID and the Global Fund to Fight AIDS, Tubercu-
losis and Malaria. By 2008, there were 1,292 health pro-
moters and 293 microscopists. Domiciliary spraying
with residual insecticides was a principal malaria con-
trol program, protecting 235,615 people. Almost 30,000
bed nets impregnated with insecticides were distributed
in 2007. Rice cultivation was shifting from flooding dur-
ing the crop growth phase to intermittent dry periods to
control pyrethroid resistant vectors [6].
Vectors
During the 1970s, 98% of the anopheline fauna was
Anopheles benarrochi, where P. falciparum and P. vivax
were endemic [18]. However, Anopheles albimanus
may now be the primary malaria vector in coastal Peru
[3]. Others argue it is An. pseudopunctipennis [26], the
more efficient vector. Regardless, peak vector popula-
tions occur at the rainy season’s end [2].
In contrast, Amazonian rain disrupts Anopheles larval
habitat. Greatest rainfall occurs between June and August.
Rain is more persistent in the below sea level Amazon,
limiting Anopheles breeding. During the Amazonian dry
season, swamps and pools form where mosquitoes breed
and spread malaria [19].
Anopheles darlingi was the major Peruvian Amazon vec-
tor prior to its elimination in the 1960s. Its reintroduction
likely enhanced the epidemics of the late 1990s [17,19,27].
Anopheles darlingi was absent in 1991 in Iquitos, but
present when P. falciparum infections rapidly increased.
It made up more than 90% of the Anopheles around
Iquitos during the rainy season, when most epidemic
cases occurred, and remained the major dry season vec-
tor [27]. While An. darlingi’s reintroduction replaced
An. benarrochi in the eastern and central Peruvian
Amazon, An. benarrochi was the most important mal-
aria vector in the western Amazon and limited eastern
localities in the late 1990s [17,18,25,28].
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As the 20th century began, malaria was treated with
quinine and later plasmoquine and quinacrine [2]. In
1965, cases were chloroquine (CQ) sensitive on the
Ecuadorian, Colombian, and Brazilian borders [17]. CQ
resistance was reported on Putumayo River in the epi-
demics of Gueppi, Yubineto-Angusilla, and Alamo on
the Colombian border in 1979 and 1980 [21,29]. CQ re-
sistance was later reported in 1986 at Aquarico Rio,
Alto Napo, and on the Pastaza river and its tributaries
on the Ecuadorian border [21].
Amazon in vivo studies suggested that P. falciparum
had reduced CQ and sulphadoxine-pyrimethamine (SP)
sensitivity during 1993 to 1997. However, the Health
Ministry did not consider them coordinated because of
varying methods [5,30]. By the end of the 1990s, the Na-
tional Malaria Program and Loreto Public Health De-
partment provided malaria diagnosis and free CQ
treatment as the first line medication, SP as the second,
and quinine with clindamycin or tetracycline as the third
for Plasmodium falciparum infection. Drug treatment
varied by location, but CQ treatment was widely inef-
fective [17]. In 1996, SP replaced CQ as the first line
treatment in central and eastern Amazon and was re-
placed by a seven day course of quinine plus tetracycline
in 1997, based on limited in vivo efficacy data and drug
resistance monitoring by the National Malaria Control
Program [5].
The WHO recommended in vivo drug trials, which
were conducted on the Pacific coast and the Amazon to
assess the efficacy of CQ and SP. Caballococha in east-
ern Loreto and Iquitos had similar SP resistance in 1998
(56%, RII/RIII) [31]. In western Loreto, SP use was min-
imal because CQ had been the first line treatment until
late 2002, though SP was occasionally used between
1997 and 1999 [5,24]. This was reflected in drug resist-
ance; only 14.3% of patients had adequate clinical and
parasitological response to CQ, but 92.3% had adequate
clinical and parasitological response to SP in 2000.
Molecular findings agreed [25]. In a 1999 study, coastal
parasites had RII and RIII resistance to CQ between 53%
and 65%, but RII and RIII resistance to SP varied from 0
to 10% [24]. SP and SP plus artesunate (AS) treatment
efficacies were found to be 97% and 99% respectively for
P. falciparum [3]. In Iquitos, mefloquine (MQ) and MQ
plus AS had 97% and 99% efficacy for P. falciparum
treatment [5].
Peru was one of the first countries in the Americas
to adopt artemisinin-based combination therapy (ACT)
for P. falciparum infection after its implementation
in Southeast Asia. This decision was reached at a
national malaria treatment policy meeting in Lima in
2000 after extensive clinical trials throughout Peru
with support from USAID, CDC, and the US NavalMedical Laboratory [5]. The coast would use AS plus
SP and the Amazon, AS plus MQ [5,32]. New first,
second, and third line drug treatments were approved
in August, 2000, while pregnant women continued to
be treated with quinine plus clindamycin [5]. AS plus
MQ therapy was implemented in and around Iquitos
in 2001. In the northwestern Amazon, CQ was used
for the first line treatment for P. falciparum in 2002.
By January 2003, AS plus MQ was used in this region
as well [25]. In Iquitos, changing drug policies de-
creased SP resistance, though CQ resistance remained
constant. Molecular studies showed that the removal
of SP drug pressure resulted in the decline of highly
resistant parasites [23,33]. The Health Ministry shif-
ted from generic to commercial drugs in 1999 [5].
This decision increased the cost of anti-malarials,
though there was a reduction in time lost to disability
in the Amazon [34].
The national treatment strategy for P. vivax infec-
tions was three days of CQ and seven days of prima-
quine (PQ), but compliance after the first three days
was poor with a recrudescence risk [35]. For example,
along the Iquitos-Nauta road, only 62.2% of patients
completed their CQ and primaquine P. vivax treatment
due to local beliefs [36]. As of 2007, pregnant women
were treated with CQ during pregnancy and with PQ
after [37]. There were also limited reports of CQ-
resistant P. vivax [38].
Plasmodium falciparum population dynamics
Microsatellite markers and mutations associated with
drug resistance have been used to analyze Peruvian P.
falciparum and P. vivax populations in Peru and give
insight into population structure and response to medi-
cations [17,23,33,35,39-44]. There were at least five
major clonal P. falciparum lineages present in Peru
based on isolates collected between 1998 and 2000.
It was hypothesized that there were at least two CQ and
SP resistant clonal lineages that had spread from
Amazonian Brazil, two SP sensitive clonal lineages that
were descendants of parasites from the coastal Peru,
Ecuador, or Colombia and had spread to the Peruvian
interior, and a vestigial Peruvian Amazon interior clonal
lineage [45]. Regarding P. vivax, it appears there is a lack
of outbreeding, few polyclonal infections, and high link-
age disequilibrium [35].
Diagnostic-resistant Plasmodium falciparum parasites
Where microscopy cannot be used as the primary diag-
nostic tool, rapid diagnostic tests (RDTs) are being con-
sidered as an alternate tool in Peru. Most commercial
malaria RDTs use histidine rich protein 2 (HRP2) as the
target antigen, which is only presented by P. falciparum.
In Peru, up to 40% of P. falciparum parasites had HRP2
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HRP2-based RDTs and therefore non-HRP2 based RDTs
must be considered.
Conclusions
Peru should be applauded for the success of its malaria
control programs. It has learned to mitigate the migration
of naïve hosts to malarious regions, provide adequate
medical intervention, and monitor parasites for drug re-
sistance. Malaria control programs in other countries
should plan for the migration of naïve hosts to economic
centers, maintain political will even as malaria dwindles,
and prepare for the failure of primary anti-malarials and
insecticides. Armed with this knowledge and techniques,
Peru can control and possibly eliminate malaria.
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